Appili Therapeutics Inc.
APLI.TOTSXHealthcare● Active
$0.02
+$0.00(+0.00%)
Market Cap$1925490
P/E Ratio—
52W High$0.04
52W Low$0.01
Appili Therapeutics Inc. (APLI.TO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · APLI.TO · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.10M | $0.83M | $0.33M | $1.39M | $0.00M |
| Cost of Revenue | $0.00M | $0.00M | $0.01M | $0.00M | $0.01M |
| Gross Profit | $0.10M | $0.83M | $0.33M | $1.39M | ($0.01M) |
| Gross Margin %(computed) | 100.00% | 100.00% | 98.12% | 100.00% | — |
| Operating Expenses | |||||
| R&D Expenses | $7.33M | $5.62M | $3.81M | $21.46M | $11.49M |
| G&A Expenses | $2.85M | $3.05M | $4.44M | $4.61M | $4.79M |
| Total Operating Expenses | $0.29M | $2.92M | $8.11M | $24.95M | $16.28M |
| Operating Income | ($0.19M) | ($2.16M) | ($7.91M) | ($24.68M) | ($16.30M) |
| Operating Margin %(computed) | -190.00% | -261.39% | — | — | — |
| Interest Income | $0.00M | $0.02M | $0.03M | $0.03M | $0.12M |
| Interest Expense | $3.50M | $1.63M | $1.10M | $1.55M | $0.07M |
| Income Before Tax | ($2.61M) | ($3.71M) | ($9.21M) | ($25.08M) | ($14.95M) |
| Income Tax Expense | $0.02M | $0.07M | $0.04M | $0.04M | ($0.63M) |
| Net Income | ($2.62M) | ($3.78M) | ($9.24M) | ($25.12M) | ($14.33M) |
| Net Margin %(computed) | — | -456.96% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.02 | $-0.03 | $-0.08 | $-0.38 | $-0.24 |
| Wtd Avg Shares | 121.27M | 121.27M | 113.73M | 66.73M | 59.18M |
| EBITDA | $0.36M | ($2.07M) | ($8.10M) | ($23.51M) | ($14.87M) |
| EBITDA Margin %(computed) | 358.98% | -249.78% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CAD · M
Explore more Appili Therapeutics Inc. data
About Appili Therapeutics Inc. (APLI.TO) Income Statement
Appili Therapeutics Inc. (APLI.TO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, APLI.TO reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.00B) — a net profit margin of -2613.12%.
Frequently asked questions
APLI.TO · 4 questionsAppili Therapeutics Inc. (APLI.TO) reported revenue of $0.00B for 2025, down 87.9% year-over-year.
APLI.TO revenueAPLI.TO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09